Adenovirus vector vaccines

Q4 Pharmacology, Toxicology and Pharmaceutics

Drug Delivery System Pub Date : 2022-11-25 DOI:10.2745/dds.37.421

H. Mizuguchi, M. Tachibana, F. Sakurai

{"title":"Adenovirus vector vaccines","authors":"H. Mizuguchi, M. Tachibana, F. Sakurai","doi":"10.2745/dds.37.421","DOIUrl":null,"url":null,"abstract":"Recently, importance of vaccines for treatment and prevention of emerging and re-emerging infectious diseases has been re-recognized. A replication-incompetent adenovirus（Ad） vector vaccine expressing virus antigen proteins is one of the most advanced platforms as a novel vaccine because an Ad vector vaccine can be rapidly applicable to pandemic. In this review, we describe the basic properties of an Ad vector for vaccine, in addition to the summary of the development of an Ad vector vaccine for emerging and re-emerging infectious diseases, including Coronavirus disease 2019（COVID-19）, worldwide.Alternate :抄録非増殖型アデノウイルスベクターは、in vivoへの直接投与において優れた遺伝子導入活性を示すことから、病原体由来の抗原タンパク質を発現させることにより、新興・再興感染症に対するワクチンベクターとして積極的な開発が進められてきた。最近では、新型コロナウイルス感染症（COVID-19）に対するワクチンとして、欧米中露において迅速な実用化がなされた。本稿では、アデノウイルスベクターの特性、COVID-19に対するアデノウイルスベクターワクチンの特徴、およびアデノウイルスベクターワクチンの可能性について解説する。","PeriodicalId":11331,"journal":{"name":"Drug Delivery System","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Delivery System","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2745/dds.37.421","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}

引用次数: 0

Abstract

Recently, importance of vaccines for treatment and prevention of emerging and re-emerging infectious diseases has been re-recognized. A replication-incompetent adenovirus（Ad） vector vaccine expressing virus antigen proteins is one of the most advanced platforms as a novel vaccine because an Ad vector vaccine can be rapidly applicable to pandemic. In this review, we describe the basic properties of an Ad vector for vaccine, in addition to the summary of the development of an Ad vector vaccine for emerging and re-emerging infectious diseases, including Coronavirus disease 2019（COVID-19）, worldwide.Alternate :抄録非増殖型アデノウイルスベクターは、in vivoへの直接投与において優れた遺伝子導入活性を示すことから、病原体由来の抗原タンパク質を発現させることにより、新興・再興感染症に対するワクチンベクターとして積極的な開発が進められてきた。最近では、新型コロナウイルス感染症（COVID-19）に対するワクチンとして、欧米中露において迅速な実用化がなされた。本稿では、アデノウイルスベクターの特性、COVID-19に対するアデノウイルスベクターワクチンの特徴、およびアデノウイルスベクターワクチンの可能性について解説する。

查看原文本刊更多论文

腺病毒载体疫苗

recently,importance of vaccines for treatment and prevention of emerging and re-emerging infectious diseaseshas been re-recognized. A replication-incompetent adenovirus (Ad) vector vaccine expressing virusantigen proteins is one of the most高级platforms as a novel vaccine because an Ad vectorvaccine can be rapidly applicable to pandemic. In this review，we describe the basic properties of an Ad vector for vaccinein addition to the summary of the development of an Ad vector vaccine for emerging and re-emerginginfectious diseases, including Coronavirus disease 2019 (COVID-19)，worldwide.Alternate:摘要非增殖腺病毒载体是in由于在直接给vivo的过程中显示出了出色的基因导入活性，所以通过表达来自病原体的抗原蛋白质，积极开发了针对新兴、再兴感染症的疫苗载体。最近，作为针对新型冠状病毒感染(COVID-19)的疫苗，在欧美、中俄迅速实现了实用化。本文将对腺病毒载体的特性、针对COVID-19的腺病毒载体疫苗的特征以及腺病毒载体疫苗的潜力进行讲解。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Drug Delivery System Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science

自引率

0.00%

发文量